{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T01:08:27Z","timestamp":1779066507943,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"MOST | National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82125006"],"award-info":[{"award-number":["82125006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82125006"],"award-info":[{"award-number":["No. 82125006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EMBO Mol Med"],"DOI":"10.1038\/s44321-024-00180-5","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T10:56:43Z","timestamp":1733223403000},"page":"1-2","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting to BMP9 to restrain flare-up of fibrodysplasia ossificans progressiva"],"prefix":"10.1038","volume":"17","author":[{"given":"Qiwen","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2836-1081","authenticated-orcid":false,"given":"Quan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"key":"180_CR1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153792","volume":"132","author":"S Aykul","year":"2022","unstructured":"Aykul S, Huang L, Wang L, Das NM, Reisman S, Ray Y, Zhang Q, Rothman N, Nannuru KC, Kamat V et al (2022) Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1. J Clin Investig 132:e153792","journal-title":"J Clin Investig"},{"key":"180_CR2","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1038\/s41591-023-02561-8","volume":"29","author":"M Di Rocco","year":"2023","unstructured":"Di Rocco M, Forleo-Neto E, Pignolo RJ, Keen R, Orcel P, Funck-Brentano T, Roux C, Kolta S, Madeo A, Bubbear JS et al (2023) Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Med 29:2615\u20132624","journal-title":"Nat Med"},{"key":"180_CR3","doi-asserted-by":"publisher","first-page":"303ra137","DOI":"10.1126\/scitranslmed.aac4358","volume":"7","author":"SJ Hatsell","year":"2015","unstructured":"Hatsell SJ, Idone V, Wolken DMA, Huang L, Kim HJ, Wang L, Wen X, Nannuru KC, Jimenez J, Xie L et al (2015) ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med 7:303ra137","journal-title":"Sci Transl Med"},{"key":"180_CR4","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1172\/JCI93521","volume":"127","author":"K Hino","year":"2017","unstructured":"Hino K, Horigome K, Nishio M, Komura S, Nagata S, Zhao C, Jin Y, Kawakami K, Yamada Y, Ohta A et al (2017) Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva. J Clin Investig 127:3339\u20133352","journal-title":"J Clin Investig"},{"key":"180_CR5","doi-asserted-by":"publisher","first-page":"15438","DOI":"10.1073\/pnas.1510540112","volume":"112","author":"K Hino","year":"2015","unstructured":"Hino K, Ikeya M, Horigome K, Matsumoto Y, Ebise H, Nishio M, Sekiguchi K, Shibata M, Nagata S, Matsuda S et al (2015) Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Proc Natl Acad Sci USA 112:15438\u201315443","journal-title":"Proc Natl Acad Sci USA"},{"key":"180_CR6","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.stemcr.2018.10.007","volume":"11","author":"K Hino","year":"2018","unstructured":"Hino K, Zhao C, Horigome K, Nishio M, Okanishi Y, Nagata S, Komura S, Yamada Y, Toguchida J, Ohta A et al (2018) An mTOR signaling modulator suppressed heterotopic ossification of fibrodysplasia ossificans progressiva. Stem Cell Rep 11:1106\u20131119","journal-title":"Stem Cell Rep"},{"key":"180_CR7","doi-asserted-by":"publisher","unstructured":"Kaplan FS, Shore EM, Pignolo RJ (2024) Fibrodysplasia ossificans progressiva emerges from obscurity. Trends Mol Med. https:\/\/doi.org\/10.1016\/j.molmed.2024.08.010","DOI":"10.1016\/j.molmed.2024.08.010"},{"key":"180_CR8","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1007\/s11010-022-04446-9","volume":"477","author":"X Meng","year":"2022","unstructured":"Meng X, Wang H, Hao J (2022) Recent progress in drug development for fibrodysplasia ossificans progressiva. Mol Cell Biochem 477:2327","journal-title":"Mol Cell Biochem"},{"key":"180_CR9","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/jbmr.4655","volume":"37","author":"RJ Pignolo","year":"2022","unstructured":"Pignolo RJ, Baujat G, Hsiao EC, Keen R, Wilson A, Packman J, Strahs AL, Grogan DR, Kaplan FS (2022) Palovarotene for fibrodysplasia ossificans progressiva (FOP): results of a randomized, placebo-controlled, double-blind phase 2 trial. J Bone Min Res 37:1891\u20131902","journal-title":"J Bone Min Res"},{"key":"180_CR10","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/jbmr.2728","volume":"31","author":"RJ Pignolo","year":"2016","unstructured":"Pignolo RJ, Bedford-Gay C, Liljesthr\u00f6m M, Durbin-Johnson BP, Shore EM, Rocke DM, Kaplan FS (2016) The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment. J Bone Min Res 31:650\u2013656","journal-title":"J Bone Min Res"},{"key":"180_CR11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/ng1783","volume":"38","author":"EM Shore","year":"2006","unstructured":"Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho T-J, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M et al (2006) A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38:525\u2013527","journal-title":"Nat Genet"},{"key":"180_CR12","doi-asserted-by":"publisher","unstructured":"Zhao C, Inada Y, Motoike S, Kamiya D, Hino K, Ikeya M (2024) BMP-9 mediates fibroproliferation in fibrodysplasia ossificans progressiva through TGF-\u03b2 signaling. EMBO Mol Med https:\/\/doi.org\/10.1038\/s44321-024-00174-3 (this issue)","DOI":"10.1038\/s44321-024-00174-3"}],"container-title":["EMBO Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00180-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44321-024-00180-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44321-024-00180-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:43:16Z","timestamp":1779064996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44321-024-00180-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,13]]}},"alternative-id":["180"],"URL":"https:\/\/doi.org\/10.1038\/s44321-024-00180-5","relation":{},"ISSN":["1757-4684"],"issn-type":[{"value":"1757-4684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interest statement"}}]}}